|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US6849708B1
(en)
|
1986-05-05 |
2005-02-01 |
The General Hospital Corporation |
Insulinotropic hormone and uses thereof
|
|
US5614492A
(en)
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
|
US5120712A
(en)
|
1986-05-05 |
1992-06-09 |
The General Hospital Corporation |
Insulinotropic hormone
|
|
US5118666A
(en)
|
1986-05-05 |
1992-06-02 |
The General Hospital Corporation |
Insulinotropic hormone
|
|
US7138486B2
(en)
|
1986-05-05 |
2006-11-21 |
The General Hospital Corporation |
Insulinotropic hormone derivatives and uses thereof
|
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
|
US5321008A
(en)
|
1991-01-10 |
1994-06-14 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
|
|
US5609885A
(en)
|
1992-09-15 |
1997-03-11 |
Alza Corporation |
Osmotic membrane and delivery device
|
|
EP1288224B1
(en)
|
1993-08-09 |
2008-06-25 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Therapeutic peptide derivatives
|
|
US5574008A
(en)
|
1994-08-30 |
1996-11-12 |
Eli Lilly And Company |
Biologically active fragments of glucagon-like insulinotropic peptide
|
|
US5512549A
(en)
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
|
US5574010A
(en)
|
1994-11-14 |
1996-11-12 |
The Regents Of The University Of California |
Treatment of pancreatic tumors with peptide YY and analogs thereof
|
|
US5739106A
(en)
*
|
1995-06-07 |
1998-04-14 |
Rink; Timothy J. |
Appetite regulating compositions
|
|
DE69720190T2
(de)
|
1996-02-02 |
2003-12-11 |
Alza Corp |
Implantierbares system mit verzögerter freisetzung von leuprolid
|
|
US6156331A
(en)
|
1996-02-02 |
2000-12-05 |
Alza Corporation |
Sustained delivery of an active agent using an implantable system
|
|
US6132420A
(en)
|
1996-02-02 |
2000-10-17 |
Alza Corporation |
Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
|
|
US6395292B2
(en)
|
1996-02-02 |
2002-05-28 |
Alza Corporation |
Sustained delivery of an active agent using an implantable system
|
|
US6261584B1
(en)
|
1996-02-02 |
2001-07-17 |
Alza Corporation |
Sustained delivery of an active agent using an implantable system
|
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
|
ZA981610B
(en)
|
1997-03-24 |
1999-08-26 |
Alza Corp |
Self adjustable exit port.
|
|
MY125849A
(en)
|
1997-07-25 |
2006-08-30 |
Alza Corp |
Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
|
|
CA2315890C
(en)
|
1997-12-22 |
2009-08-11 |
Alza Corporation |
Rate controlling membranes for controlled drug delivery devices
|
|
EP1041968B1
(en)
|
1997-12-29 |
2004-03-03 |
Alza Corporation |
Osmotic delivery system with membrane plug retention mechanism
|
|
ATE342051T1
(de)
|
1997-12-30 |
2006-11-15 |
Alza Corp |
Verabreichungssystem für wirkstoffe mit einem membranstöpsel
|
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
|
US6720407B1
(en)
|
1998-08-28 |
2004-04-13 |
Eli Lilly And Company |
Method for administering insulinotropic peptides
|
|
EP1137667B1
(en)
|
1998-12-07 |
2004-11-17 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Analogues of glp-1
|
|
DE69906132T2
(de)
|
1998-12-31 |
2003-12-18 |
Alza Corp., Mountain View |
Osmotisches verabreichungsystem mit raumsparenden kolben
|
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
PT1180121E
(pt)
|
1999-05-17 |
2004-03-31 |
Conjuchem Inc |
Peptidos insulinotropicos de longa duracao
|
|
US7022674B2
(en)
|
1999-12-16 |
2006-04-04 |
Eli Lilly And Company |
Polypeptide compositions with improved stability
|
|
AU773354B2
(en)
|
1999-12-21 |
2004-05-20 |
Intarcia Therapeutics, Inc. |
Valve for osmotic devices
|
|
AU2001263230B2
(en)
|
2000-05-19 |
2005-03-10 |
Amylin Pharmaceuticals, Llc |
Treatment of acute coronary syndrome with glp-1
|
|
DE60137876D1
(de)
|
2000-06-16 |
2009-04-16 |
Lilly Co Eli |
Analoge des Glucagon-ähnlichen Peptids-1
|
|
AU2002228608A1
(en)
|
2000-12-13 |
2002-06-24 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
|
JP2005506956A
(ja)
|
2001-06-01 |
2005-03-10 |
イーライ・リリー・アンド・カンパニー |
長時間作用性glp−1製剤
|
|
US7163688B2
(en)
|
2001-06-22 |
2007-01-16 |
Alza Corporation |
Osmotic implant with membrane and membrane retention means
|
|
AU2002322403A1
(en)
|
2001-08-23 |
2003-03-10 |
Eli Lilly And Company |
Glucagon-like peptide-1 analogs
|
|
GB0121709D0
(en)
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
|
US7041646B2
(en)
|
2001-10-05 |
2006-05-09 |
Bayer Pharmaceuticals Corporation |
Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
|
|
CA2841097A1
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin and g-csf fusion proteins
|
|
WO2004002565A1
(en)
|
2002-06-26 |
2004-01-08 |
Alza Corporation |
Minimally compliant, volume efficient piston for osmotic drug delivery systems
|
|
AU2003278929A1
(en)
|
2002-10-18 |
2004-05-13 |
Amylin Pharmaceuticals, Inc. |
Treatment of pancreatitis with amylin
|
|
US7014636B2
(en)
|
2002-11-21 |
2006-03-21 |
Alza Corporation |
Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
|
|
US7207982B2
(en)
|
2003-03-31 |
2007-04-24 |
Alza Corporation |
Osmotic pump with means for dissipating internal pressure
|
|
US20050175701A1
(en)
|
2004-02-10 |
2005-08-11 |
Alza Corporation |
Capillary moderator for osmotic delivery system
|
|
KR20140011431A
(ko)
|
2004-02-11 |
2014-01-28 |
아밀린 파마슈티칼스, 엘엘씨. |
선택가능한 특성을 갖는 하이브리드 폴리펩티드
|
|
US20070027105A1
(en)
|
2005-07-26 |
2007-02-01 |
Alza Corporation |
Peroxide removal from drug delivery vehicle
|
|
CN101400698A
(zh)
*
|
2006-03-15 |
2009-04-01 |
诺沃-诺迪斯克有限公司 |
胰岛淀粉样多肽衍生物
|
|
EP2020990B1
(en)
|
2006-05-30 |
2010-09-22 |
Intarcia Therapeutics, Inc |
Two-piece, internal-channel osmotic delivery system flow modulator
|
|
PL2359808T3
(pl)
|
2006-08-09 |
2013-10-31 |
Intarcia Therapeutics Inc |
Osmotyczne systemy dostawcze i zespoły tłokowe
|
|
EP2240155B1
(en)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
WO2010046357A1
(en)
*
|
2008-10-21 |
2010-04-29 |
Novo Nordisk A/S |
Amylin derivatives
|
|
ES2622877T3
(es)
|
2009-01-22 |
2017-07-07 |
Keybioscience Ag |
Tratamiento para la obesidad
|
|
EP2405934B1
(en)
|
2009-03-12 |
2014-03-26 |
Nordic Bioscience A/S |
Treatment of diabetes and metabolic syndrome
|
|
RU2603093C2
(ru)
|
2010-04-15 |
2016-11-20 |
Дженентек, Инк. |
Антитела против полиубиквитина и способы их применения
|
|
WO2012162547A2
(en)
*
|
2011-05-25 |
2012-11-29 |
Amylin Pharmaceuticals, Inc. |
Long duration dual hormone conjugates
|
|
EP2718315B1
(en)
|
2011-06-10 |
2017-12-27 |
Novo Nordisk A/S |
Pramlintide derivatives
|
|
PL2838914T3
(pl)
|
2012-04-19 |
2017-11-30 |
Novo Nordisk A/S |
Analogi ludzkiej amyliny
|
|
WO2015155151A1
(en)
|
2014-04-07 |
2015-10-15 |
Novo Nordisk A/S |
Double-acylated glp-1 compounds
|
|
CN106687474A
(zh)
|
2014-09-04 |
2017-05-17 |
诺和诺德股份有限公司 |
新型胰淀素和降钙素受体激动剂
|
|
AR103954A1
(es)
|
2015-03-18 |
2017-06-14 |
Zealand Pharma As |
Análogos de amilina
|
|
AR109514A1
(es)
|
2016-09-09 |
2018-12-19 |
Zealand Pharma As |
Análogos de amilina
|